Preventive Electroacupuncture Alleviates Oxidative Stress and Inflammation via Keap1/Nrf2/HO-1 Pathway in Rats with Cyclophosphamide-Induced Premature Ovarian Insufficiency. 2022

Yang Chen, and Rui Zhao, and Xiang Li, and Yun-Peng Luan, and Li-Wei Xing, and Xiao-Juan Zhang, and Jing Wang, and Xiao-Yan Xia, and Rong Zhao
Nanjing University of Chinese Medicine, Nanjing 210023, China.

Electroacupuncture (EA) is a popular therapeutic therapy for premature ovarian insufficiency (POI). However, little has been known about the underlying processes of EA therapy. To investigate the benefit of EA and reveal the mechanism, thirty SD female rats were allocated into the control, model, sham, EA, and GnRHa groups at random. Vaginal smears were used to monitor the rats' estrous cycle. Serum liver and renal function (ALT, AST, BUN, and Cr), sex hormone (FSH, E2, and AMH), oxidative stress markers (SOD, GSH, and MDA), and inflammatory cytokine (IL6, IL1β, and TNFα) levels were measured by enzyme-linked immunosorbent assay (ELISA). Their ovary morphology was observed by hematoxylin-eosin staining. Transmission electron microscope was used to remark the ultrastructure of the granulocytes. Protein and gene expressions of Keap1/Nrf2/HO-1 pathway were detected by western blot and RT-PCR. Compared with the model group, in the EA group, the levels of serum sex hormones recovered to normal levels. Moreover, it reduced oxidative stress in rats, as demonstrated by increased SOD and GSH levels and decreased MDA levels. Meanwhile, Keap1 mRNA and protein expression dropped considerably in the EA group, while the mRNA and protein expressions of Nrf2 and HO-1 increased. We found that preventive EA might rescue rats with CTX-induced ovarian dysfunction. The anti-inflammatory and antioxidative stress properties of EA, which elevated the Keap1/Nrf2/HO-1 signaling pathway, might be the underlying mechanism. Furthermore, as compared to GnRHa, electroacupuncture did not raise the burden of the liver (ALT and AST) or the kidney (BUN and Cr). Electroacupuncture has a meaningful impact and a sufficient level of safety, making it useful for therapeutic setting in POI.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D000072019 Kelch-Like ECH-Associated Protein 1 An adaptor protein characterized by an N-terminal BTB-POZ DOMAIN and six KELCH REPEATS that functions as a substrate for the E3 UBIQUITIN LIGASE complex. It negatively-regulates NF-E2-RELATED FACTOR 2 by targeting it for ubiquitination and degradation by the PROTEASOME. It also represses genes regulated by ANTIOXIDANT RESPONSE ELEMENTS. KEAP-1 Protein,KEAP1 Protein,KEAP 1 Protein,Kelch Like ECH Associated Protein 1
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013482 Superoxide Dismutase An oxidoreductase that catalyzes the reaction between SUPEROXIDES and hydrogen to yield molecular oxygen and hydrogen peroxide. The enzyme protects the cell against dangerous levels of superoxide. Hemocuprein,Ag-Zn Superoxide Dismutase,Cobalt Superoxide Dismutase,Cu-Superoxide Dismutase,Erythrocuprein,Fe-Superoxide Dismutase,Fe-Zn Superoxide Dismutase,Iron Superoxide Dismutase,Manganese Superoxide Dismutase,Mn-SOD,Mn-Superoxide Dismutase,Ag Zn Superoxide Dismutase,Cu Superoxide Dismutase,Dismutase, Ag-Zn Superoxide,Dismutase, Cobalt Superoxide,Dismutase, Cu-Superoxide,Dismutase, Fe-Superoxide,Dismutase, Fe-Zn Superoxide,Dismutase, Iron Superoxide,Dismutase, Manganese Superoxide,Dismutase, Mn-Superoxide,Dismutase, Superoxide,Fe Superoxide Dismutase,Fe Zn Superoxide Dismutase,Mn SOD,Mn Superoxide Dismutase,Superoxide Dismutase, Ag-Zn,Superoxide Dismutase, Cobalt,Superoxide Dismutase, Fe-Zn,Superoxide Dismutase, Iron,Superoxide Dismutase, Manganese
D015671 Electroacupuncture A form of acupuncture with electrical impulses passing through the needles to stimulate NERVE TISSUE. It can be used for ANALGESIA; ANESTHESIA; REHABILITATION; and treatment for diseases.
D016649 Primary Ovarian Insufficiency Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections. The most commonly known genetic cause is the expansion of a CGG repeat to 55 to 199 copies in the 5' untranslated region in the X-linked FMR1 gene. Gonadotropin-Resistant Ovary Syndrome,Ovarian Failure, Premature,Resistant Ovary Syndrome,FMR1-Related Primary Ovarian Insufficiency,Fragile X Premature Ovarian Failure,Fragile X-Associated Primary Ovarian Insufficiency,Hypergonadotropic Ovarian Failure, X-Linked,Premature Ovarian Failure,Premature Ovarian Failure 1,Premature Ovarian Failure, X-Linked,Primary Ovarian Insufficiency, Fragile X-Associated,X-Linked Hypergonadotropic Ovarian Failure,FMR1 Related Primary Ovarian Insufficiency,Fragile X Associated Primary Ovarian Insufficiency,Gonadotropin Resistant Ovary Syndrome,Hypergonadotropic Ovarian Failure, X Linked,Ovarian Insufficiency, Primary,Premature Ovarian Failure, X Linked,Primary Ovarian Insufficiency, Fragile X Associated,X Linked Hypergonadotropic Ovarian Failure
D051267 NF-E2-Related Factor 2 A basic-leucine zipper transcription factor that was originally described as a transcriptional regulator controlling expression of the BETA-GLOBIN gene. It may regulate the expression of a wide variety of genes that play a role in protecting cells from oxidative damage. Nfe2l2 Protein,Nuclear Factor (Erythroid-Derived 2)-Like 2 Protein,Nuclear Factor E2-Related Factor 2,NF E2 Related Factor 2,Nuclear Factor E2 Related Factor 2

Related Publications

Yang Chen, and Rui Zhao, and Xiang Li, and Yun-Peng Luan, and Li-Wei Xing, and Xiao-Juan Zhang, and Jing Wang, and Xiao-Yan Xia, and Rong Zhao
January 2023, BioMed research international,
Yang Chen, and Rui Zhao, and Xiang Li, and Yun-Peng Luan, and Li-Wei Xing, and Xiao-Juan Zhang, and Jing Wang, and Xiao-Yan Xia, and Rong Zhao
June 2023, Environmental science and pollution research international,
Yang Chen, and Rui Zhao, and Xiang Li, and Yun-Peng Luan, and Li-Wei Xing, and Xiao-Juan Zhang, and Jing Wang, and Xiao-Yan Xia, and Rong Zhao
March 2021, Brain research bulletin,
Yang Chen, and Rui Zhao, and Xiang Li, and Yun-Peng Luan, and Li-Wei Xing, and Xiao-Juan Zhang, and Jing Wang, and Xiao-Yan Xia, and Rong Zhao
November 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Yang Chen, and Rui Zhao, and Xiang Li, and Yun-Peng Luan, and Li-Wei Xing, and Xiao-Juan Zhang, and Jing Wang, and Xiao-Yan Xia, and Rong Zhao
March 2023, Ecotoxicology and environmental safety,
Yang Chen, and Rui Zhao, and Xiang Li, and Yun-Peng Luan, and Li-Wei Xing, and Xiao-Juan Zhang, and Jing Wang, and Xiao-Yan Xia, and Rong Zhao
November 2022, Current issues in molecular biology,
Yang Chen, and Rui Zhao, and Xiang Li, and Yun-Peng Luan, and Li-Wei Xing, and Xiao-Juan Zhang, and Jing Wang, and Xiao-Yan Xia, and Rong Zhao
May 2024, Molecular biotechnology,
Yang Chen, and Rui Zhao, and Xiang Li, and Yun-Peng Luan, and Li-Wei Xing, and Xiao-Juan Zhang, and Jing Wang, and Xiao-Yan Xia, and Rong Zhao
January 2024, Archives of biochemistry and biophysics,
Yang Chen, and Rui Zhao, and Xiang Li, and Yun-Peng Luan, and Li-Wei Xing, and Xiao-Juan Zhang, and Jing Wang, and Xiao-Yan Xia, and Rong Zhao
June 2021, Experimental and therapeutic medicine,
Yang Chen, and Rui Zhao, and Xiang Li, and Yun-Peng Luan, and Li-Wei Xing, and Xiao-Juan Zhang, and Jing Wang, and Xiao-Yan Xia, and Rong Zhao
January 2022, Neuroreport,
Copied contents to your clipboard!